PCSK9赛道风云再起。6月9日,默沙东宣布口服PCSK9抑制剂Enlicitide治疗高胆固醇血症的两项III期研究达到了主要终点。这是全球首个III期研究成功的口服PCSK9抑制剂。港交所医药企业IPO大年。6月9日,港交所官网显示,药捷安康通过港交所聆讯即将上市,其专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。在过去的一天里,国内外医药市场还有哪些热点值得关注?让氨基君带你一探究竟...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.